AFTER 8th_NIF
> ATTENDEES
> INVESTORS
> PRESENTERS
> SPONSORS
> SUPPORTERS

20-minute presenters

Acelot, Inc.

Acelot develops small molecules for challenging targets in diseases with high unmet need using a computational platform developed by Founder Dr. Ambuj Singh. Acelot’s first-in-class development candidate, ACE-2223, targets misfolded TDP-43 for the treatment of sporadic ALS. ACE-2223 disrupts misfolded TDP-43 and restores nuclear TDP-43 function. ACE-2223 is well characterized in vitro and in two aggressive ALS animal models.  ACE-2223 is entering IND enabling studies in 2025 to prepare for first-in-human studies.

https://www.acelot.com

Actinogen Medical Ltd.
[ASX: ACW]

Actinogen is a late Phase 2 clinical-stage biopharmaceutical company developing a once-a-day oral small molecule to treat Alzheimer's Disease and Major Depressive Disorder. Its lead molecule Xanamem works by controlling levels of the "stress hormone" cortisol in the brain without altering plasma cortisol.  Cortisol levels have long been associated with both AD and MDD and in a recent Phase 2a clinically and statistically signficant improvements were seen in depressive symptoms. A phase 2b/3 is on-going in AD in Australia and the US.​

www.actinogen.com.au

Brenig Therapeutics Inc.

Brenig Therapeutics is a science-driven venture with a focus on developing innovative medicines dedicated to advancing the field of neuroinflammation and lysosomal pathologies through cutting-edge research and strategic partnerships.​

www.brenigther.com

Cognition Therapeutics, Inc.
[​NASDAQ: CGTX]

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and geographic atrophy secondary to dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.​​

www.cogrx.com

Cognito Therapeutics, Inc.

Cognito Therapeutics is a late-stage clinical neurotechnology company pioneering disease-modifying treatments for neurodegenerative diseases. Its lead product, Spectris™, uses non-invasive auditory and visual neuromodulation to enhance gamma frequency brain activity, with the goal of slowing brain atrophy and functional decline in Alzheimer's disease. Cognito is committed to developing transformative, technology-driven interventions to address unmet needs in the treatment of CNS diseases. Cognito is headquartered in Cambridge, MA.​

www.cognitotx.com

Cumulus Neuroscience

Cumulus Neuroscience is a world-leading medical AI technology company with large datasets and multiple years of experience helping BioTech’s and Pharma accelerate CNS drug development.  We are bringing to market AccelADx, which is a uniquely scalable, AI-enabled dementia screening tool which will revolutionise the early detection of Alzheimer’s. Accelerating Alzheimer’s Diagnosis (AccelADx) enables precision clinical trial patient stratification and clinical care using neurophysiological biomarkers and AI. Our platform includes our FDA-approved EEG headset and tablet-based versions of validated assessments.​

www.cumulusneuro.com

EG 427

EG 427 is developing DNA medicines based on non-replicative HSV-1 vectors for prevalent indications.

EG110A is our lead program currently in Ph1b/2a trial in neurogenic detrusor overactivity (NDO) delivering safety and efficacy read-out in this high-value indication(s) in early ’26.

Our HERpes-based Modular Expression System (HERMES) platform is the foundation for a pipeline in multiple highly prevalent indications.

www.eg427.com

EuMentis Therapeutics, Inc.

EuMentis Therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of novel circuit-selective medicines to treat neurodevelopmental and other central nervous system conditions.  EuMentis is planning to initiate a phase 2 clinical trial in autism spectrum disorder with EM-113 and a phase 2 trial in Schizophrenia with its best-in-class PDE10 inhibitor, EM-221 in 2025.

www.eumentistx.com

Gain Therapeutics, Inc.
[NASDAQ: GANX]

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287 is being evaluated in the clinic for the treatment of Parkinson’s disease and other neurodegenerative diseases.​

www.gaintherapeutics.com

Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer’s disease – Galimedix’s initial areas of focus. The Company’s approach targets toxic Aβ oligomers and protofibrils.  Many studies have indicated that these oligomers and protofibrils are an underlying cause of neurodegenerative diseases of the eye. And, recent approvals and promising Phase 3 results of anti-Aβ drugs also have validated them as a key target in Alzheimer’s disease. Compelling pre-clinical data support the potential of Galimedix’s product candidates to slow or stop neurodegeneration and also restore lost neuronal function. A Phase 2 proof-of-concept study in dry AMD with lead program, topical GAL-101, is in preparation with strong support from partner, Théa Open Innovation (TOI). Clinical studies in other indications are planned for GAL-101 and for GAL-201, Galimedix oral drug for Alzheimer´s disease.

www.galimedix.com

Noema Pharma AG

Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025.

Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including EQT, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises.

www.noemapharma.com

Oryzon Genomics, S.A.
[BME: ORY]

A public clinical-stage biopharma company developing epigenetics for CNS disorders and Oncology. c.50 highly-qualified professionals located in Barcelona, Boston and San Diego. Listed in Spain, aiming at NASDAQ-listing.

Two uncorrelated clinical-stage compounds: vafidemstat (Phase III-ready, CNS) and iadademstat (Phase II, oncology).

Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor, administered to over 400 subjects. Vafidemstat is now Phase III-ready for borderline personality disorder (BPD) following an End-of-Phase II meeting with the FDA. The drug has shown promising results in reducing agitation and aggression in psychiatric patients in a Phase IIa basket trial and in a global randomized, double blind Phase IIb trial in BPD (PORTICO), with final results presented at ECNP-2024. Preparing Phase III PORTICO-2 trial in BPD. Vafidemstat is also being investigated for treating negative symptoms of schizophrenia in a randomized, double-blind Phase IIb trial.Plans to expand to precision medicine in rare CNS disorders, starting with a Phase I/II trial in Kabuki syndrome.

Iadademstat, a best-in-class LSD1 inhibitor, is in clinical development for AML and solid tumors. PoC with strong clinical activity in combo with azacitidine in a Phase II in unfit AML patients, and encouraging signals in 2L-ED-SCLC. Ongoing trials in R/RFlt3mut+ AML (in combo with gilteritinib), 1L AML (in combo with venetoclax/azacitidine) and neuroendocrine tumors, plus new trials under a CRADA agreement with NCI-NIH (1L SCLC in combo with ICI, 1L AML) and additional investigator-initiated trials.

www.oryzon.com/en

Reunion Neuroscience, Inc.
[tsx:reun / NASDAQ:REUN]

Reunion is a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions that serve as safe, fast-acting, short duration therapies for underserved mental health disorders, beginning with postpartum depression (PPD). We envision a day when depression isn’t just a disorder that can be managed, but instead is curable. We relentlessly pursue the development of safer therapeutics that provide durable antidepressive effects for the millions of people whose needs are not met by the current standard of care.​

www.reunionneuro.com

STALICLA SA

STALICLA SA is a Swiss clinical-stage biopharmaceutical company, revolutionizing the treatment of neurodevelopmental (NDD) and wider neuropsychiatric disorders. 

The company has developed a clinically validated neuro precision development platform, successfully delivering stratified patient subgroups and advancing tailored treatment options. 

Its lead NDD asset, STP1, and a second NDD asset are set to enter Phase 2 trials with expected readouts within 24-28 months. STP7 (Mavoglurant), is also being advanced for Phase 3 trials, fully funded by the US government. 

We are currently raising a series C of $60m to recite the Phase 2 development.

www.stalicla.com

Teitur Trophics ApS

Teitur Trophics: Advancing Neurodegeneration Treatments

Teitur Trophics is a biopharmaceutical company dedicated to developing transformative treatments for neurodegenerative diseases, including Huntington's Disease, Parkinson's Disease, and Frontotemporal Dementia. The company company is founded on pioneering research conducted at Aarhus University, where scientists uncovered a novel pathway that plays a critical role in maintaining neuronal survival and function. This pathway uniquely targets three key pillars of neurodegeneration: improving mitochondrial function, enhancing lysosomal function, and preserving synaptic integrity. By addressing these interconnected mechanisms, we aim to protect and restore the health of neurons, ultimately slowing or even halting disease progression.

Our lead program, TT-P34, represents a groundbreaking advance in the field of neurodegeneration. TT-P34 is a first-in-class peptide therapy that has demonstrated potent efficacy in preclinical studies, including its ability to slow or halt disease progression in animal models of Huntington's Disease and Parkinson's Disease. Importantly, the compound is designed with patient convenience in mind, offering a once-weekly subcutaneous injection, reducing treatment burden and improving adherence. With a strong foundation of preclinical data supporting its safety and efficacy, TT-P34 is set to enter first-in-human studies in Q2 2025, where it will initially be tested in healthy volunteers. This milestone marks a significant step toward bringing a much-needed, disease-modifying therapy to patients suffering from devastating neurodegenerative disorders.

At Teitur Trophics, we believe that innovation in science is the key to addressing the complex challenges of neurodegeneration. By focusing on a holistic approach to neuronal health and leveraging cutting-edge research, we are committed to developing therapies that not only extend life but also preserve its quality for patients and their families.

www.teiturtrophics.com

Tonix Pharmaceuticals Holding Corp.
[NASDAQ: TNXP]

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges.​

www.tonixpharma.com

VectorY tx

We are an Amsterdam-based biotech company founded in 2020 with a mission to develop vectorized antibody treatments for people with neurodegenerative diseases, enabling longer, better lives.

Antibody treatments have wide applicability in neurodegenerative diseases that are known to be complex and difficult to treat. Our cutting-edge vectorized antibody technology combines highly selective therapeutic antibodies with one-time AAV-based delivery to the CNS. We are advancing a development pipeline of potentially disease-modifying treatments for ALS, Huntington’s, and Parkinson’s disease.

www.vectorytx.com

10-minute presenters

ABILITY Neurotech

ABILITY Neurotech is a pioneering neurotechnology company that develops brain-computer interface (BCI) systems focused on enabling motor control and communication for individuals with severe paralysis. Our flagship product integrates advanced microelectrode arrays with sophisticated decoding algorithms to translate neural signals into precise digital commands, allowing users to control external devices and communicate through thought alone. ABILITY Neurotech stands out for its unique approach to developing fully implantable BCI systems, with first-in-human (FIH) testing expected in 2025.

www.wysscenter.ch/advances/ability

Autifony Therapeutics Limited

Autifony Therapeutics Limited is a clinical stage biotechnology company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform.​

www.autifony.com

Avata Biosciences

AVAT-021 is Avata Biosciences de-risked & expedited Epilepsy & Schizophrenia lead asset

Despite a wide range of currently available medicines, most epilepsy patients are still unable to adequately control their seizures which is why there will always be a high demand for new medicines.

CBD has been proven to be an effective new medicine for rare epilepsy, however, the liquid formulation is impractical and too costly for adult patients to access.

For the first time, Avata’s technology has successfully created a CBD medicine (AVAT-021) in a capsule which adult patients will easily access to effectively treat their seizures.

In addition to the FOS program, Avata has entered into a partnership with Oxford University to assess AVAT-021, planning to start a Phase 2 study in patients with first episode Schizophrenia in 2025.

www.avatabio.com

Bloom Science, Inc.

Bloom Science is redefining medicine by creating innovative therapies that harness the body’s natural metabolic and neurological pathways. Inspired by the therapeutic benefits of the ketogenic diet, Bloom’s approach targets multiple mechanisms simultaneously to provide safer, more effective solutions for obesity, Dravet syndrome, ALS, and other complex conditions.

Our lead program, BL-001, is a live biotherapeutic product reverse engineered to replicate the ketogenic diet’s clinical efficacy. BL-001 has demonstrated proof of mechanism and has been observed to be safe and tolerable, with Bloom planning Phase 2 clinical trials in both obesity and Dravet syndrome.

The IrisRx™ discovery platform powers Bloom’s pipeline by integrating cutting-edge science and a proprietary knowledgebase. This platform enables the development of novel, multi-pathway therapeutics through gut commensal microbes and synthetic biology, delivering innovative treatments with broad therapeutic potential. Backed by top-tier investors and a team of industry veterans, Bloom Science is advancing a deep pipeline to transform patient care and create lasting clinical impact.

www.bloomscience.com

Brain Tx

Based on our vision that Artificial Intelligence Powered Theronostic Technology is the next significant innovation in medicine, we are designing proprietary platforms that will objectively provide novel drug discovery, rapid development of genetically engineered neurons, and precise biometric endpoints to accelerate clinical approvals.

We intend to advance SigNAiture, a Patented Deep Learning Powered platform, that objectively measures Neuronal health in synergy of Confocal microscopy, HD-Multielectrode array, Raman Spectroscopy, and Digital PCR.

SigNAiture will support BRAiN platforms, and will be marketed for Licensure to Pharma, Biotech, and Psychedelic partners for their Neuronal research and Drug Discovery programs.

www.braintx.bio

Engrail Therapeutics, Inc.

Engrail is a clinical-stage pharmaceutical company with a rich pipeline of precision-targeted neuroscience programs designed to improve the lives of patients with neuropsychiatric and neurodevelopmental diseases.​

www.engrail.com

Enveric BioSciences, Inc.
[NASDAQ: ENVB​]

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogen therapeutics for the treatment of neuropsychiatric disorders.

www.enveric.com

JCR Pharmaceuticals Co., Ltd.
[​TYO: 4552]

JCR Pharmaceuticals is a fully integrated Biopharmaceutical company with focus on rare neurological diseases and an established portfolio in neurological diseases. JCR has approximately 1,000 employees and subsidiaries in the US, Europe and Brazil. JCR is the first company who brought a Biologic to regular approval that was designed to cross the blood-brain-barrier for the treatment of a disease with significant neurological sequalae. Partnerships with pharmaceutical companies are at the core of JCR's portfolio acceleration strategy or to make its blood-brain-barrier transport technology available to enable partner's assets to cross the blood-brain barrier.

www.jcrpharm.co.jp

Lys Therapeutics

First-in-class biotherapies against neurological diseases.

​Lys Therapeutics is a biotechnology company pioneering a revolutionary approach to treat unmet medical needs in patients suffering from neurovascular or neurodegenerative disorders by targeting blood-brain barrier (BBB) dysfunction.

Targeting neuroinflammation to tackle neurodegeneration.

www.lystherapeutics.com

Magdalena Biosciences, Inc.

Magdalena Biosciences, Inc (Magdalena), incorporated in 2023 as a JV between Jaguar Health and Filament Health, has developed a paradigm shifting approach to drug development, reducing the time from project initiation to clinical trial commencement to 12-24 months (vs 4-6 years for small molecules), saving time, money but, more importantly, improving the probability of success through the development of botanical drugs (under FDA Botanical Guidance) with a focus on plants with a medicinal history of use, frequently used for neuropsychiatric indications by traditional psychiatrists. Magdalena has prepared a pipeline of effective, plant-based psychoactive drugs that are safe for daily dosing and can be used on a long-term basis. Taking advantage of the Jaguar Health library of plant candidates for neuropsychiatric indications (based on input from an impressive Scientific Strategy Team of ethnobotanists, physicians and ethnopharmacologists, knowledgeable of the medicinal properties of plants) and the Filament Health botanical drug development capabilities including their success at filing IND applications with a human dossier of safety rather than animal toxicology data consistent with FDA Botanical Guidance, we have raised seed capital and used it to prepare our first IND to be filed in 2025. We have exciting FDG PET scan data from our first drug candidate, MB2500, demonstrating activity in the prefrontal cortex as well as neuronal connectivity and remodeling in addition to preclinical animal data in the MK801 model of cognitive deficit suggesting MB2500 is able to reverse cognitive deficit as well or better than the classic drug for treating dementia, donepezil, as well as additional data from models for anxiety and depression. MB2500 is based on a plant used in natura by traditional healers. Our first indication with MB2500 is a treatment to improve executive dysfunction in ADHD with a follow-on indication of the improvement of cognitive function in schizophrenia.

www.magdalenabiosciences.com

Neurocentrx Pharma Ltd.

Neurocentrx is a UK psychiatry biotech developing an abuse-deterrent oral ketamine and companion digital safety app solution for 1st FDA approval of oral ketamine for severe depression across clinical and home treatment settings

We are seeking ~$20M over 24 months for clinical proof-of-concept in treatment-resistant major depression, with market approval possible within 4 years. 

We are biotech entrepreneurs and leading psychiatrists from Kings College London and McLean Hospital in Boston.

We have funding support from the Wellcome Trust and UK Medical Research Council for ongoing trials in secondary indications of bipolar depression and severe anorexia.

www.neurocentrx.com

Nine Square Therapeutics, Inc.

Nine Square Therapeutics, founded by ATP and top scientists at UCSF, is developing innovative treatments for neurodegenerative diseases by targeting genetically validated pathways, with a focus on correcting autophagy/mitophagy dysfunction​.

www.ninesquaretx.com

Psilera Inc.

Psilera is a biopharmaceutical company focused on developing groundbreaking therapeutics for neurodegenerative diseases by creating a new class of neurological medicines. Their proprietary drug discovery engine combines novel chemistry with a technology-enabled platform (Psilera Third Eye) to design next-generation neuroplastogens at the atomic level. Psilera's lead asset, PSIL-006, is a non-hallucinogenic psilocybin derivative for the treatment of frontotemporal dementia (FTD). With a deep commitment to improving the patient experience through scientific excellence, Psilera is transforming the lives of individuals affected by devastating diseases. Welcome to the new era of mindful medicine.

www.psilera.com

ReST Therapeutics SAS

ReST Therapeutics is pioneering transformative therapies for patients with significant unmet needs in psychiatry and neurodegeneration.

Our lead program, RST-01, aims to revolutionize PTSD treatment by focusing on early intervention after traumatic events and adopting a patient-centric clinical strategy. RST-01 targets specific NMDA receptor sub-types, which are crucial for alleviating abnormal fear extension and preventing pathological memory consolidation.

Over the past three years, we have developed pre-clinical proof of concept (POC) in collaboration with top international academic experts and institutions. These data, along with our completed IND-enabling studies, position us to initiate a Phase I clinical study in 2025.

Additionally, ReST Therapeutics is expanding its portfolio and intellectual property with three more pre-clinical candidates targeting neuroinflammation-related neurodegenerative diseases.

www.rest-therapeutics.com

Sinaptica Therapeutics, Inc.

Sinaptica has developed a new form of personalized weekly brain stimulation for Alzheimer’s Disease (AD) that has been granted FDA breakthrough status based on unprecedented published sham-controlled Phase 2 data-- significantly slowing mild-to-moderate (M/M) AD on all functional and cognitive endpoints at 6 months, and on the primary and all key secondaries at 12 months in all three domains: cognition, function, and behavior, with virtually no side-effects.

Sinaptica’s technology is a new powerful form of rTMS with personalization (via concurrent pairing with EEG), precision (via Neuronavigation) and a proprietary ML algorithm and treats AD by enhancing neuroplasticity via neuromodulation of the Default mode network (DMN), a novel brain network responsible for episodic memory and strongly implicated in AD. Sinaptica is emerging as a leader in personalized precision brain stimulation with a connectomics-based platform that can address multiple brain disease states, starting with Alzheimer's and MCI.

www.sinapticatx.com

VOD PRESENTERS

InflammaSense

InflammaSense is revolutionizing mental health clinical trials with cutting-edge inflammation-sensing technology and AI-enabled solutions. Our non-invasive devices deliver real-time inflammation insights, enhancing trial enrichment and reducing costs. Paired with advanced AI models integrated into EMR systems, we identify reliable patients with unparalleled precision. Focused on mental health as our first use case, we're streamlining patient selection and monitoring to accelerate breakthroughs in conditions like PTSD, MDD, and GAD. Most importantly our clinical trial enrichment tools will radically reduce trial costs.

 🚀 #MedTech #Innovation #BioelectronicMedicine #AI #MentalHealth #ClinicalTrials

www.inflammaSense.com

Myrobalan Therapeutics, Inc.

Myrobalan is a private asset-based pharmaceutical company located in Massachusetts. Our strategy focuses on addressing the brain microenvironment to restore neuronal function through highly selective, oral, small-molecule therapies targeting demyelination and neuroinflammation, which are key drivers of many CNS disorders. Our lead program, MRO-001, is a highly selective CSF1R inhibitor aimed at reducing neuroinflammation in ALS and other neurodegenerative diseases, with the first clinical trial set to be initiated in mid-2025. Our second program, MRO-002, is a GPR17 antagonist designed to promote myelin repair across a broad spectrum of neurodegenerative disorders.​

www.myrotx.com

Tactile Therapeutics, Inc.

Tactile Therapeutics has identified novel molecular glues from its degradation platform to target  RIPK3 and MLKL, proteins that may be instrumental in neuroinflammation and related neuronal cell death.  The company was founded by experienced industry veterans with a deep understanding of inflammation linked cell death. Tactile is developing novel molecular glues to  attenuate necroptosis. The necroptosis pathway has been implicated in a variety of neurological disease pathologies and is increasingly associated with disease progression in degenerative conditions.  In fact, necroptotic cell death may be a key driver of worsening dementia and cognitive decline in neurodegenerative diseases such as Alzheimer disease and progressive multiple sclerosis.  Tactile Therapeutics has successfully built its novel degraders with a highly efficient structure-based drug design approach and now has Glues and PROTAC degraders that demonstrate potent anti-necroptotic activity.  Most recently, we have successfully designed novel molecular glues for RIPK3 that selectively degrade the active form of RIPK3 and cause complete ablation of the necroptosis pathway. Tactile is Seed funded by institutional investors and is now commencing a new round of financing to move its programs to IND-readiness.​

www.tactiletx.com